Popular:
Syros Pharmaceuticals, Inc. (SYRS)
Intrinsic Value
DCF Not Suitable for SYRS
Market cap ($0.00B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.
Alternative Approach:
Use relative valuation (P/E, P/S) vs. peer group.
Syros Pharmaceuticals, Inc. (SYRS) Intrinsic Value
DCF-based fair value calculation with Bear, Base, and Bull scenarios
Frequently Asked Questions
Is SYRS stock undervalued or overvalued?
Insufficient data to compute DCF valuation for SYRS. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.
What is SYRS's intrinsic value?
Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.
How is SYRS's fair value calculated?
Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For SYRS, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.